Bone-targeted therapy in castration-resistant prostate cancer: Where do we stand?

Review

Abstract: Introduction: In the last years, there have been significant developments in the therapeutic armamen

Palabras claves:

Denosumab, prostatic neoplasms, Radium-223, theranostic nanomedicine, Zoledronic acid

Autores:

Alvarez-Maestro M., Cathelineau X., Debruyne F., Diego M. Carrión, Lorenzo G.D., Maio M.D., Martinez-Piñéiro L., Paul A., Rivas J.G., Saad F., Sanchez-Salas R., Sartor O.

Fuentes:

scopus